GlaxoSmithKline
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Topotecan Pharmacokinetic Characterization Study
- First Posted Date
- 2006-08-09
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 15
- Registration Number
- NCT00361803
- Locations
- πΊπΈ
GSK Investigational Site, Scottsdale, Arizona, United States
SERETIDE 50/500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Chronic Obstructive Pulmonary Disease
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2006-08-09
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1270
- Registration Number
- NCT00361959
- Locations
GSK Investigational Site
Partially-blind (Observer-blind) Study of Safety and Immunogenicity of Two Malaria Vaccines in Ghanaian Children
- Conditions
- Malaria
- Interventions
- Biological: GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049Biological: Rabipur
- First Posted Date
- 2006-08-04
- Last Posted Date
- 2018-02-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 540
- Registration Number
- NCT00360230
- Locations
- π¬π
GSK Investigational Site, Kumasi, Ghana
An Open-Label Extension Study Of Lamotrigine In Subjects With Bipolar Disorder
- Conditions
- Bipolar Disorder
- First Posted Date
- 2006-08-03
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 11
- Registration Number
- NCT00360126
- Locations
- π¦πΊ
GSK Investigational Site, New Farm, Queensland, Australia
Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB
- Conditions
- Neisseria MeningitidisHaemophilus Influenzae Type b
- Interventions
- Biological: MenHibrix (Hib-MenCY-TT)Biological: Hib conjugate vaccine (ActHIB)
- First Posted Date
- 2006-08-03
- Last Posted Date
- 2016-12-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 270
- Registration Number
- NCT00359983
- Locations
- πΊπΈ
GSK Investigational Site, Pittsburgh, Pennsylvania, United States
Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment
- First Posted Date
- 2006-08-02
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 33
- Registration Number
- NCT00359463
- Locations
- π³πΏ
GSK Investigational Site, Christchurch, New Zealand
Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine
- Conditions
- Papillomavirus VaccinesInfections, Papillomavirus
- Interventions
- Biological: HPV investigational vaccine GSK568893A, different formulationsBiological: CervarixTM
- First Posted Date
- 2006-08-02
- Last Posted Date
- 2020-01-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 383
- Registration Number
- NCT00359619
- Locations
- π§πͺ
GSK Investigational Site, Wilrijk, Belgium
Observational Pharmacokinetic Study Of GW679769 In Subjects With Renal Impairment
- First Posted Date
- 2006-08-01
- Last Posted Date
- 2017-08-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT00358813
- Locations
- πΊπΈ
GSK Investigational Site, Minneapolis, Minnesota, United States
AVANDAMET Versus Metformin And Sulphonylurea In People With Poorly Controlled Type 2 Diabetes
- Conditions
- Non-Insulin-Dependent Diabetes Mellitus
- First Posted Date
- 2006-08-01
- Last Posted Date
- 2009-05-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 544
- Registration Number
- NCT00359112
- Locations
- π¬π§
GSK Investigational Site, Sheffield, United Kingdom
Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide
- First Posted Date
- 2006-08-01
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT00358540
- Locations
- πΊπΈ
GSK Investigational Site, Houston, Texas, United States